The Think NENs Global Educational Program for Primary Care Physicians has been launched by the International Neuroendocrine Cancer Alliance (INCA). The Think NENs Global Educational
Neuroendocrine carcinomas (NECs) are uncommon and aggressive cancers with limited treatment options after the failure of platinum-based therapies. A recently concluded phase II trial investigated
The University of Pennsylvania is now enrolling patients in the new phase 1/2 multi-center clinical trial for CAR T cell therapy. The trial includes patients
NETRF is pleased to announce that Daniel Halperin, MD, one of our distinguished Board of Scientific Advisors members, has been appointed Vice Chair of Clinical
A phase I CAR T-cell clinical trial targeting the molecule IL13Rα2 found on the surface of some tumors is being conducted at the University of
The Neuroendocrine Tumor Research Foundation is excited to share an important update in the field of neuroendocrine tumor (NET) treatment. On August 6, 2024, Exelixis
A new first-in-human clinical trial at the National Institutes of Health in Bethesda, Maryland, is exploring the use of an antibody-drug conjugate (ADC), ADCT-701, in
The U.S. Food and Drug Administration approved Lutathera® as the first therapy specifically for patients 12 to 17 years of age who have somatostatin receptor-positive
The U.S. Food and Drug Administration recently authorized a new technology called histotripsy to treat tumors in the liver, including neuroendocrine tumors. The noninvasive Edison®
A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can
